aap Implantate AG (FRA:AAQ) Aap 2008: Sales Growth To EUR 31.2 Million (+ 11%)

aap Implantate AG (FRA:AAQ) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------



aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment, achieved in the fourth quarter of the financial year 2008 - according to preliminary figures - quarterly sales of EUR 7.1 million (- 24% to fourth quarter 2007). In contrast to the fourth quarter 2008, the fourth quarter 2007 was influenced by more orders from global partners. Total sales of the financial year 2008 went up to EUR 31.2 million, a year-to-year increase of 11%.

In 2008, the group companies active in the field of medical biomaterials ("aap bio implants group"), achieved sales of EUR 19.4 million (previous year: EUR 18.8 million, + 3%). This development is based on the considerably cautious customers' order behavior (reduction of inventories) as well as delays in planned approvals of new products.

The Berlin based trauma & orthopaedics division of the company reached for the full financial year 2008 a strong organic sales increase of 28% to EUR 11.8 million (previous year: EUR 9.2 million).

+-------------------------------------------------------------------+ | In EUR million | 2008 | 2007 | Changes | |--------------------------------+----------+----------+------------| | Fourth quarter sales | 7.1 | 9.4 | - 24% | |--------------------------------+----------+----------+------------| | Financial year sales | 31.2 | 28.0 | + 11% | |--------------------------------+----------+----------+------------| | * thereof trauma & | 11.8 | 9.2* | + 28% | | orthopaedics | | | | |--------------------------------+----------+----------+------------| | * thereof aap bio | 19.4 | 18.8* | + 3% | | implants group | | | | |-------------------------------------------------------------------| | * Variational presentation to the segment report as of 31st of | | December 2007 results in the modified presentation of the | | distribution of a product. | +-------------------------------------------------------------------+





The publication of the full annual financial statements 2008 is planned for April 17, 2009. ___________ aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotical carriers, implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main, Dusseldorf as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003.

Please address any queries to: aap Implantate AG, Nanette Hüdepohl, Investor & Public Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; fax: +49 30 7501 9290; n.huedepohl@aap.de

--- End of Message ---

aap Implantate AG Lorenzweg 5 Berlin Germany

WKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;

aap Implantate AG

www.aap.de

ISIN: DE0005066609

Stock Identifier: XFRA.AAQ